High expression of CD38 on the surface of malignant plasma cells in MM led to the development of CD38 targeting monoclonal antibodies (mAbs), daratumumab (dara) and isatuximab for the treatment of MM (33–38). This evidence concerns the gene CD38 and Miyoshi myopathy.